Login to Your Account



Mismatch endometrial bid proper fit for Tesaro's PD-1

By Randy Osborne
Staff Writer

Thursday, April 27, 2017

With just-approved PARP inhibitor Zejula making its way in the marketplace, Tesaro Inc. has turned its phase I dose-escalating trial with anti-PD-1 antibody TSR-042 into a registration experiment.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription